Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.71 |
| ▸ | NPY4R | P50391 | 8/20 | 0.71 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.71 |
| ▸ | NPY1R | P25929 | 6/20 | 0.71 |
| ▸ | CALCR | P30988 | 4/20 | 0.69 |
| ▸ | TFPI | P10646 | 3/20 | 0.64 |
| ▸ | GLP1R | P43220 | 2/20 | 0.63 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.63 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578732 | 0.94 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31146614 | 0.94 | NPY2R (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30658322 | 0.93 | NPY2R (0.68) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30578733 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30578734 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30578729 | 0.93 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30495647 | 0.92 | NPY2R (0.77) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30435943 | 0.92 | NPY2R (0.65) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30432747 | 0.92 | CALCR (0.70) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31105560 | 0.92 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595314-B2 | Antibody specific for GPC3 and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | disclosed |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2026-01-01 | — | — | US | disclosed |
| EP-4647436-A2 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | Sapreme Technologies B.V. (NL) | 2025-11-12 | — | — | EP | disclosed |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-28 | — | — | US | disclosed |
| EP-3897735-B1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECH BV (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250302983-A1 | Saponin Conjugates | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-02 | — | — | US | disclosed |
| EP-4619417-A1 | NANOCONJUGATES CONTAINING PDGFR-BETA LIGANDS AND USES THEREOF | Universitat Autònoma de Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| US-20250243250-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIV AUTÒNOMA DE BARCELONA UAB (ES) | 2025-07-31 | — | — | US | disclosed |
| US-20250236679-A1 | ANTI-DLL3 ANTIBODY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-24 | — | — | US | disclosed |
| US-11376326-B2 | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-07-05 | — | — | US | disclosed |
| EP-4015003-A1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-06-22 | — | — | EP | disclosed |
| EP-4010079-A1 | IDENTIFICATION AND ELIMINATION OF HCMV-INFECTED CELLS | Stichting VU (NL) | 2022-06-15 | — | — | EP | disclosed |
| EP-4007604-A1 | ANTIBODY SPECIFIC FOR GPC3 AND METHODS OF USE THEREOF | R.P. Scherer Technologies, LLC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220153875-A1 | ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3557260-B1 | GPC3-TARGETING DRUG WHICH IS ADMINISTERED TO PATIENT RESPONSIVE TO GPC3-TARGETING DRUG THERAPY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-107964042-B | Target tissue specific antigen binding molecules | 中外制药株式会社 | 2022-04-19 | — | — | CN | disclosed |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2022-04-14 | — | — | US | disclosed |
| CN-114190218-A | Method for constructing rainforest plant community in near-tropical zone | 广州普邦园林股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3943108-A1 | ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595314-B2 | Antibody specific for GPC3 and methods of use thereof | IGLV6-57, IGSF11, VSIG8 | NPY2R 1177/4885NPY4R 1712/4885NPY5R 2198/4885 |
| US-20250302983-A1 | Saponin Conjugates | EPCAM, CD47, SHBG | NPY2R 3179/4885NPY4R 3993/4885NPY5R 2679/4885 |
| US-20220153875-A1 | ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN | MICA, TNFSF10, HLA-A | NPY2R 4829/4885NPY4R 4807/4885NPY5R 4782/4885 |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, FCGR3B | NPY2R 3745/4885NPY4R 4102/4885NPY5R 2790/4885 |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, EGFR | NPY2R 3140/4885NPY4R 3902/4885NPY5R 1884/4885 |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | CD40, FCGR1A, TNFSF10 | NPY2R 2123/4885NPY4R 1770/4885NPY5R 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.